Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of “Moderate Buy” by Brokerages

Solid Biosciences Inc. (NASDAQ:SLDB) has received an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and eleven have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $16.00.

SLDB has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a report on Thursday, January 22nd. Wedbush reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Solid Biosciences in a report on Wednesday, March 11th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Solid Biosciences in a research report on Friday. Guggenheim started coverage on shares of Solid Biosciences in a research note on Friday. They set a “buy” rating and a $26.00 target price for the company. Finally, Citigroup restated a “market outperform” rating on shares of Solid Biosciences in a research report on Wednesday, December 17th.

Insider Buying and Selling at Solid Biosciences

In other Solid Biosciences news, insider Gabriel Brooks sold 28,335 shares of Solid Biosciences stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total transaction of $182,477.40. Following the sale, the insider owned 96,708 shares of the company’s stock, valued at $622,799.52. The trade was a 22.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO David T. Howton sold 37,771 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $6.44, for a total value of $243,245.24. Following the transaction, the chief operating officer owned 116,753 shares of the company’s stock, valued at $751,889.32. This trade represents a 24.44% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 597,672 shares of company stock valued at $3,816,546. 13.63% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Bollard Group LLC bought a new position in Solid Biosciences in the 2nd quarter valued at about $1,761,000. Boxer Capital Management LLC bought a new stake in shares of Solid Biosciences during the 3rd quarter worth about $3,702,000. Geode Capital Management LLC raised its position in shares of Solid Biosciences by 184.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,510,153 shares of the company’s stock worth $7,356,000 after buying an additional 979,294 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of Solid Biosciences by 28.9% in the 2nd quarter. Franklin Resources Inc. now owns 1,599,173 shares of the company’s stock worth $7,788,000 after acquiring an additional 358,473 shares during the period. Finally, ProShare Advisors LLC bought a new position in shares of Solid Biosciences in the second quarter valued at approximately $80,000. 81.46% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: Guggenheim started coverage with a Buy and a $26 price target (implies ~272% upside from recent levels), giving formal street-level momentum and a large upside case for the stock. Guggenheim starts coverage (Benzinga)
• Positive Sentiment: Needham reaffirmed Buy with a $19 price target, signaling continued analyst conviction in the company’s clinical progress and longer-term value. Needham reaffirms buy (Benzinga)
• Positive Sentiment: Chardan reaffirmed its Buy rating and $15 target, adding to the cluster of upgrade/reaffirmation headlines that can attract investor attention and trading demand. Chardan reaffirms buy (TickerReport)
• Positive Sentiment: Solid reported positive interim Phase 1/2 INSPIRE data for SGT-003 at the 2026 MDA meeting; the readout highlights generally favorable tolerability in 41 dosed participants—this is the primary fundamental catalyst supporting higher valuations. SGT-003 interim data (GlobeNewswire)
• Neutral Sentiment: The company issued its Q4 and full-year 2025 results and broader business updates; the release contains operational context and program timelines that investors will parse for runway and development plans. Q4 & full-year 2025 results (FinanzNachrichten)
• Negative Sentiment: SLDB missed Q4 EPS expectations (reported -$0.53 vs. consensus -$0.48), underlining ongoing losses and near-term profitability risk that likely capped the stock’s upside today. Earnings press release (Quartr)

Solid Biosciences Trading Down 1.3%

Shares of Solid Biosciences stock opened at $7.03 on Monday. The stock has a market capitalization of $547.71 million, a price-to-earnings ratio of -3.48 and a beta of 2.64. Solid Biosciences has a twelve month low of $2.41 and a twelve month high of $8.72. The business’s 50 day simple moving average is $6.43 and its 200-day simple moving average is $5.80.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.01. Sell-side analysts predict that Solid Biosciences will post -2.84 earnings per share for the current year.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.